WASHINGTON — Patients who underwent Dextenza implantation had improvements in itching due to allergic conjunctivitis through 30 days, according to a study.
At the American Society of Cataract and Refractive Surgery meeting, Steven Silverstein, MD, said current treatments are adequate most of the time but do not have lasting effects and do not work as well for moderate to severe symptoms.
“[Dextenza] is an intracanalicular steroid insert that releases dexamethasone to the ocular surface in a sustained and tapered fashion for 30 days,” he said. “It’s an excellent